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One of the strategies used by tumors to evade immunosurveillance is the accumulation of extracellular adenosine, which has
immunosupressive and tumor promoting effects. The study of the mechanisms leading to adenosine formation at the tumor
interstitium are therefore of great interest in oncology. The dominant pathway generating extracellular adenosine in tumors is the
dephosphorylation of ATP by ecto-nucleotidases. Two of these enzymes acting sequentially, CD39 and CD73, efficiently hydrolyze
extracellular ATP to adenosine.They have been found to play a crucial role in a variety of tumors, but there were no data concerning
endometrial cancer, the most frequent of the invasive tumors of the female genital tract. The aim of the present work is to study the
expression of CD39 and CD73 in human endometrial cancer. We have analyzed protein and gene expression, as well as enzyme
activity, in type I endometrioid adenocarcinomas and type II serous adenocarcinomas and their nonpathological endometrial
counterparts. High levels of both enzymes were found in tumor samples, with significantly increased expression of CD39 in type
II serous tumors, which also coincided with the higher tumor grade. Our results reinforce the involvement of the adenosinergic
system in cancer, emphasizing the relevance of ecto-nucleotidases as emerging therapeutic targets in oncology.
1. Introduction
Extracellular adenosine concentration increases under
metabolically stressful conditions, notably in the tumor
microenvironment [1], where hypoxia is frequently given
[2, 3]. Such accumulation of adenosine mediates, through
four distinct receptors (A1, A2A, A2B, and A3), complex and
diverse effects that lead to tumor immunoescape [4]. This
includes cytoprotection and growth promotion of tumor
cells [5, 6], angiogenesis increase [7, 8], and suppression of
effector (antitumor) T cells [9].
Although cells are provided with adenosine transporters,
themain source of this nucleoside in the tumor interstitium is
the hydrolysis of extracellular ATP, which also accumulates in
tumors, by membrane enzymes known as ecto-nucleotidases
[6, 10]. Different families of these enzymes, acting extra-
cellularly, are responsible for the generation of adenosine
from adenine nucleotides (i.e., ATP, ADP, or AMP): (1)
the ectonucleoside triphosphate diphosphohydrolase (E-
NTPDase) family, that includes four plasma membrane-
boundmembers: NTPDase1 (CD39), NTPDase2, NTPDase3,
and NTPDase8; these enzymes are differentially expressed
and hydrolyze with different affinities nucleoside triphos-
phates and diphosphates to their monophosphate deriva-
tives (e.g., ATP and ADP to AMP); (2) the ectonucleotide
pyrophosphatase/phosphodiesterase (E-NPP) family, capable
of hydrolyzing nucleoside triphosphates to monophosphates
and pyrophosphate (PPi), such as ATP to AMP and PPi;
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(3) the alkaline phosphatase (AP) family, that includes
ubiquitous enzymes degrading broad range of substrates,
such as adenine nucleotides and PPi, releasing inorganic
phosphate (Pi); (4) the 5󸀠-nucleotidase family, with only one
member attached to the outer plasmamembrane, the ecto-5󸀠-
nucleotidase (CD73), a glycosyl phosphatidylinositol-linked
membrane-bound glycoprotein that efficiently hydrolyses
AMP to adenosine [11–13].
Two members of ecto-nucleotidases families, the E-
NTPDase CD39 and the 5󸀠-nucleotidase CD73, acting
sequentially, seem to have a crucial role in tumor-immune cell
interaction [6]. They both are expressed not only by infiltrat-
ing immune cells but also by tumor cells, and their expression
is regulated by hypoxia [10, 14]. Increased CD39 and CD73
expression has been described in various cancer types,mostly
in correlation with a poor prognosis [15–17]. Both molecules
are considered promising therapeutic targets in oncology,
and CD73 has already been proven to inhibit tumor growth
and metastasis in a breast cancer model in mice [18–20].
However, until now there were not available data concerning
ecto-nucleotidases expression in endometrial cancer (EC).
EC is the most frequent of the invasive tumors of the female
genital tract. There are two clinicopathological variants: the
estrogen-related, type I, endometrioid carcinoma, and the
nonestrogen-related, type II, nonendometrioid carcinoma
[21]. Although there are different molecular alterations that
have been already identified in EC, with different prevalence
between tumors [22, 23], there is need to decipher the
complete molecular profile of EC pathogenesis to improve
diagnosis and favor the design of new therapeutic strategies.
The aim of the present work was to study the expression
of CD39 and CD73 in endometrioid (type I) and serous (type
II) EC when compared with nontumoral endometrium. To
achieve this objective, protein and gene expression exper-
iments, as well as in situ enzyme activity assays, were
performed on human endometrial adenocarcinoma samples
and their nontumoral endometrial counterparts.
2. Materials and Methods
2.1. Samples. The ethical principles of this study adhere to
the Declaration of Helsinki, and all the procedures were
approved by the ethics committee for clinical investigation
of Bellvitge Hospital. Endometrial samples from adenocar-
cinoma (endometrioid and serous types) and their corre-
sponding nontumoral tissue (if present) were obtained from
hysterectomy specimens at the Service of Gynecology of Bel-
lvitge Hospital. Fresh samples were cut, embedded in O.C.T.
freezing media (Tissue-Tek; Sakura Finetek, Zoeterwoude,
The Netherlands), snap-frozen in a Shandon Histobath 2
(Neslab Instruments Inc., USA) at the Service of Pathology,
and stored at −80∘C until used. Alternatively, endometrial
samples were obtained from the Tumor Bank of Bellvitge
Biomedical Research Institute (IDIBELL).
Fifteen endometrioid adenocarcinomas (13 grade 1, 2
grade 2; all FIGO stage I) (56–82 years old, median 61) and
fourteen serous adenocarcinomas (grade 3; 9 FIGO stage I, 2
FIGO stage II, and 3 FIGO stage IV) (63–86 years old,median
77), and their adjacent nontumoral endometrium were used
in this study.
2.2. Endometrial Touch Prep Technique. Touch preparations
of endometrial cancer tissue samples were obtained by lightly
pressing the freshly cut tumor surface on clean glass micro-
scope slides, thus generating a tumor cell imprint. Imprints
were immediately air-dried and stored at −20∘C until further
processing. Six endometrioid adenocarcinoma tissue samples
were used to generate the touch preparations.
2.3. Immunolabeling Experiments. Immunohistochemistry
and immunofluorescence experiments were performed as
previously described for human endometrial samples [24].
Briefly, tissue sections of 10 𝜇m thick and touch preparations
were fixed in 10% phosphate-buffered formalin mixed with
cold acetone (Merck, Darmstadt, Germany) for 2.5 minutes.
Fixed samples were rinsed with PBS and preincubated for
1 hour at room temperature (RT) with PBS containing 20%
normal goat serum (Gibco, Paisley, UK) and 0.2% gelatin
(Merck). Samples were then incubated overnight at 4∘C
with the following primary antibodies: anti-human CD39
clone BU61 (Ancell Corporation, Minnesota, MN, USA) at
1/500, mouse monoclonal anti-human ecto-5󸀠-nucleotidase
(CD73) clone 4G4 (Abcam, Cambridge, UK) at 1/50, and
rabbit monoclonal anti-human cytokeratin 19 (CK19) clone
EPR1579Y (Abcam) at 1/200. After three washes in PBS,
samples were incubated for 1 hour at RT with the appropri-
ate secondary antibodies: horseradish peroxidase-conjugated
goat anti-mouse (EnVision + system; DAKO, Carpinteria,
USA), Alexa Fluor 488- or 555-goat anti-mouse or anti-rabbit
(Life Technologies, Paisley, UK). Secondary antibody alone
was routinely included as control for the experiments. Nuclei
were counterstained with haematoxylin or, alternatively, in
fluorescence assays, To-Pro-3 or DAPI (Life Technologies)
were used to visualize the nuclei. Samples weremounted with
Fluoromount aqueous mounting medium (Sigma-Aldrich,
Sant Louis, Missouri, MO, USA). The results were observed
and photographed under a light Leica DMD 108 microscope
(Leica Microsystems, Wetzlar, Germany) or, in fluorescence
assays, under a Nikon Eclipse E-800 microscope (Nikon,
Tokyo, Japan) or under a Leica TCS-SL spectral confocal
microscope (Leica).
Results from both tissue samples and touch preparations
were independently evaluated by at least two observers.
Staining distributionwas recorded. Label intensitywas scored
as negative (−), intermediate (+), or strongly positive (++).
2.4. In Situ Enzyme Activity Experiments. For enzyme his-
tochemistry, ADPase and ecto-5󸀠-nucleotidase (AMPase)
activities were localized by using the Wachstein/Meisel lead
phosphate method [24, 25] in tissue samples and in touch
preparations. Briefly, fixed samples were preincubated for 1
hour at RT in 50mM Tris-maleate buffer, pH 7.4 containing
2mM CaCl
2
and 0.25M sucrose. Enzyme reaction was
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Figure 1: (a) Immunolocalization of NTPDase1/CD39 in nontumoral human endometria ((A), (C)) and in endometrioid (B) and serous
(D) adenocarcinomas. CD39 was immunodetected in the stroma of all samples (asterisks). The expression of CD39 is remarkably higher in
tumors when compared with nontumoral endometria. Scale bars = 100𝜇m. (b) Label intensity score of CD39 in the stroma of nontumoral
human endometrium compared to endometrioid (left plot) and serous (right plot) adenocarcinoma samples. Note that both types of tumors
have a higher label score than their corresponding nontumoral endometria.
in the presence of 200𝜇M ADP or 1mM AMP, as substrate.
For CD39 and CD73 inhibition experiments, 1mM NF279
(Tocris Bioscience, Bristol, United Kingdom) and 1mM
𝛼, 𝛽-meADP (Sigma-Aldrich) were added, respectively, to
both preincubation and enzyme reaction buffers. Control
assays were performed in the absence of nucleotide. The





exactly 1 minute. Samples were counterstained with haema-
toxylin, mounted with Fluoromount aqueous mounting
medium (Sigma-Aldrich), and observed andphotographed as
described above.
2.5. Isolation of Membrane Enriched Fraction from Tissue
Homogenates. 50–100𝜇g of human tumor (endometrioid
and serous endometrial adenocarcinoma) and nontumoral
tissue samples were homogenized in a buffer containing
20mM Hepes, 250mM sucrose, 0.3mM PMSF, 1mM DTT,
1mM EGTA, and 1mMMgCl
2
(pH 7.4) using a glass homog-
enizer (VidraFoc, Barcelona, Spain). After homogenization,
samples were centrifuged at 600×g for 10 minutes at 4∘C in
a Beckman JA-20 centrifuge. The pellet was discarded and
supernatants were centrifuged at 48,000×g for 20 minutes at
4∘C in a Beckman TI-70 centrifuge.The resulting pellets were






































Figure 2: (a) Enzyme in situ histochemistry in endometrioid ((A), (B)) and in serous ((C), (D)) endometrial adenocarcinomas in the presence
of ADP as substrate, alone ((A), (C)) or together with the inhibitor NF279 ((B), (D)). Strong ADPase activity was detected in the stroma of
both types of tumors ((A), (C) dark brown deposits), while the activity was drastically reduced in the presence of the inhibitor ((B), (D)).
Scale bars = 100𝜇m. (b) ADPase enzyme activity in tissue homogenates of endometrioid (𝑛 = 12) and serous (𝑛 = 14) adenocarcinomas.
Experiments were performed in triplicate for each sample. Data are represented in arbitrary units (AU). ∗Significant differences at 𝑃 < 0.05.
(c) ADPase in situ activity in endometrial touch preparations from human endometrioid adenocarcinomas using ADP as substrate (A) and
in the absence of substrate (B). Scale bars = 50𝜇m.
resuspended in a buffer containing 20mM Hepes, 0.3mM
PMSF, and 1mM DTT (pH 7.4). Protein concentration was
determined by the method of Lowry et al. [26] using bovine
serum albumin as a standard. Samples were kept at −80∘C
until use.
2.6. Enzyme Activity Assays in Plasma Membrane Enriched
Tissue Homogenates. ADPase and AMPase activities were
determined by measuring the amount of Pi using the mala-
chite green colorimetric assay, as previously described [27].
2.7. Quantitative Real-Time PCR. Total RNA from endome-
trial tumor tissue samples was isolated using the RNeasy Plus
Mini Kit (Qiagen, Hilden, Germany), following themanufac-
turer’s protocol. Total isolated RNA (2 𝜇g) was reversely tran-
scribed into complementary DNA (cDNA) using the First
Strand cDNA Synthesis Kit (Fermentas, Thermo Scientific,
Chicago, IL, USA).
Quantitative real-time PCR (qRT-PCR) was performed
to examine the expression of CD39, NTPDase2, and CD73
genes. Designed large-scale TaqMan low-density array
(TLDA) microfluidic cards (Applied Biosystems, Foster
City, CA, USA) were used. The 384 wells of each card
were preloaded with predesigned fluorogenic TaqMan
probes and primers for CD39, NTPDase2, and CD73.
cDNA (1 𝜇g) combined with TaqMan 2X Universal PCR
Master Mix (Applied Biosystems) were loaded into each
sample-loading port. qRT-PCR reactions were carried out
using the ABI PRISM 7900HT Real-Time PCR System
(Applied Biosystems). Data were collected using the SDS
v2.1 software (Applied Biosystems) and analyzed by the
comparative Ct (ΔΔCt) quantification method using the
Expression Suite v1.0 software (Applied Biosystems). The
relative expression levels of CD39, NTPDase2, and CD73
genes were determined using 18S mRNA as an endogenous
control for normalization. Results are expressed as the
mean of the relative quantification (RQ) of the tested
transcripts (𝑛 = 7 serous adenocarcinoma samples; 𝑛 = 7
endometrioid adenocarcinoma samples) ± the standard
error of the mean (SEM). Results were obtained from five
independent experiments performed using 1𝜇g of cDNA,

























AMP(A) 𝛼, 𝛽-meADP(B) Control(C)
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Figure 3: (a) Immunolocalization of ecto-5󸀠-nucleotidase/CD73 ((A), (D)) and AMPase in situ histochemistry ((B), (C), (E), and (F)) in
endometrioid ((A)–(C)) and serous ((D)–(F)) endometrial adenocarcinomas. CD73 was immunodetected in glandular epithelial cells and in
the stroma of both types of adenocarcinomas ((A), (D)). The AMPase activity mirrors the immunolocalization ((B), (E)). The activity was
abolished in the presence of 𝛼, 𝛽-meADP ((C), (F)). Insets correspond to control experiments performed in the absence of nucleotide (no
AMP). Scale bars = 50 𝜇m ((A)–(C), (F), insets) and 250 𝜇m ((D), (E)). (b) AMPase in situ activity by enzyme histochemistry in endometrial
touch preparations. Dark precipitates in (A) correspond to the AMPase activity in the presence of AMP as substrate. The inhibitor 𝛼, 𝛽-
meADP completely abolished this activity (B). Control experiments were performed in the absence of substrate (C). Scale bars = 50𝜇m.



























































Figure 4: CD39, NTPDase2, and CD73 gene expression in human endometrial cancer tissues. Relative mRNA levels of CD39 (a), NTPDase2
(b), and CD73 (c) analyzed in serous adenocarcinomas (𝑛 = 7), normalized to 18S mRNA levels, and expressed as fold change over
endometrioid adenocarcinomas (𝑛 = 7). Data are expressed as mean ± SEM. ∗∗∗Significantly different from endometrioid (𝑃 < 0.001).
all with duplicate measurements. No signal was detected in
nontemplate controls.
2.8. Statistical Analysis. Statistical analysis was performed
using SigmaStat 3.2 software (SPSS Inc., Chicago, IL, USA).
Values are reported as the mean ± S.E.M. Student’s t-test was
used to compare the means of two independent groups of
normally distributed data.
3. Results and Discussion
Extracellular adenosine in tumors, mainly generated by the
sequential action of ecto-nucleotidases, has immunosup-
pressive effects through a broad range of actions, including
inhibition of antitumor T-cell function, modification of local
interleukin levels, and inhibition of phagocytosis (reviewed
in [28]). In this section we show and discuss our results on
the expression of the ecto-nucleotidases CD39 and CD73 in
type I and type II endometrial carcinomas.
CD39 was immunolocalized in the stroma of both
nontumoral and tumoral endometria (Figure 1(a)). For the
nonpathological endometrium the expression of CD39 has
already been previously described in associationwith stromal
cells and blood vessels [24]. Here we show that label score
was significantly higher for both endometrioid and serous
types of tumors when compared with the corresponding
nontumoral coexisting endometrium (Figure 1(b)). No CD39
labeling was found in endometrial adenocarcinoma epithelia,
as demonstrated with the double staining performed with
the anti-CD39 and anti-CK19 antibodies (see Supplemen-
tary Figure 1 in Supplementary Material available online at
http://dx.doi.org/10.1155/2014/509027).
Strong in situ ADPase activity was detected in the
tumor stroma, coinciding with the CD39 immunolocaliza-
tion (Figure 2(a)). This activity was drastically reduced with
the NTPDase inhibitor NF279, demonstrating its specificity.
Equivalent results were obtained using ATP as substrate
Mediators of Inflammation 7
for the in situ activity assay (not shown). ADPase activ-
ity measured in tumor tissue homogenates demonstrated
that serous (grade 3) adenocarcinomas had significantly
higher activity than endometrioid (grade 1) adenocarcinomas
(Figure 2(b)).
CD73 expression was strongly immunodetected in both
types of tumors, in epithelial structures and in the stroma
(Figure 3(a)), thus partially colocalizing with CK19 (Sup-
plementary Figure 2). Specific CD73 activity, demonstrated
with the inhibitor 𝛼, 𝛽-meADP, matched the immunola-
beled structures (Figure 3(a)). We have already previously
demonstrated that the expression and activity of CD73 are
abundant in nonpathological endometrium [24, 25]. Con-
sequently, due to the high expression of CD73 in tumoral
and nontumoral endometria, label score comparisons were
not possible. Moreover, no differences among tumors were
observed with the enzyme assays either in tissue slices or in
tissue homogenates (not shown).
Immunolabeling and in situ enzyme activity results
obtained with the touch prep technique were equivalent to
those obtained with tissue slices (Figures 2(c) and 3(b)).
The usefulness of the touch prep technique for diagnosis
has already been demonstrated in breast cancer with 100%
sensitivity and specificity in the evaluation of tumor margins
at the time of the surgery [29]. This technique has also
been previously used to demonstrate by immunolabeling a
decreased expression of P2X7 ATP receptor in endometrial
cancer cells [30] and also, recently, the relationship between
p53 expression and the tumor grade [31]. However, to our
knowledge, this is the first report validating the use of touch
preps for enzyme activity studies, therefore opening the
possibility of performing such studies in cytological samples.
In order to determine if the differences in CD39 protein
and ADPase activity between tumor types also involved
gene expression changes, quantitative real-time PCR analyses
were performed (Figure 4). CD39 gene expression was 2-
fold higher in serous endometrial adenocarcinoma than in
endometrioid, coinciding with the data obtained with the
protein (Figure 4(a)). These gene expression changes did
not apply to NTPDase2 (Figure 4(b)), indicating that CD39
upregulation is not a general feature of other members of
NTPDase family. No changes were detected in CD73 gene
expression between the two tumor types (Figure 4(c)).
These results on endometrial tumors add to the list of
human cancers in which CD39 is overexpressed and support
the growing body of evidence that CD39 is a potential ther-
apeutic target for cancer immunotherapy [18]. Our results
also reinforce the relevance of CD73 in tumors. Antibody-
based therapy and pharmacological approaches against
CD73 have been reported to significantly inhibit tumor
growth and improve antitumor immunity in mouse models
[28, 32].
4. Conclusions
Endometrial adenocarcinoma tumors have significantly
higher CD39 expression and activity than their nontumoral
counterparts. Moreover, stronger activities are associated
with type II serous tumors.This also coincideswith the higher
grade of these tumors, but further studies are needed to
establish statistical correlations with the tumor grade in the
case of type I endometrioid tumors.The consequences of this
highCD39 activity in endometrial tumors are increased levels
of AMP, the substrate for CD73, and also highly expressed
in these tumors, which will, in turn, generate increased
immunosuppressive levels of extracellular adenosine.
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